Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Five-Dose radiation for prostate cancer: does it work and how do patients feel?

NCT ID NCT03889119

Disease control Sponsor: Hoag Memorial Hospital Presbyterian Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 100 men with localized prostate cancer who received a condensed form of radiation called SBRT, which delivers high-dose radiation in just 5 treatments instead of the usual 42-45. Researchers are tracking how well the treatment controls cancer over time and how it affects patients' quality of life, including side effects. The goal is to see if this shorter approach is both effective and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Stereotactic body radiation therapy (SBRT) using the Elekta Versa or Agility System
What this could lead to
If successful, this could confirm that a shorter, more intense course of radiation is as effective as traditional longer treatment for prostate cancer, with fewer trips to the hospital.
What could go wrong
This is an observational follow-up study, not a randomized trial, so results may not prove SBRT is better than standard radiation. Side effects like urinary or bowel issues are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2016

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed diagnosis of adenocarcinoma of the prostate History/physical examination with digital rectal examination of the prostate * Histological evaluation of prostate biopsy with assignment of Gleason score to the biopsy material. * Clinical stage T1-3 (AJCC 7th edition). * Males age ≥ 18 * Patient must be able to provide study-specific informed consent prior to study entry. * Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire Exclusion Criteria: * Evidence of distant metastases * Regional lymph node involvement * Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer * Previous pelvic irradiation, prostate brachytherapy * Previous or concurrent cytotoxic chemotherapy for prostate cancer There are no exclusions due to co-morbid disease or illnesses except for patients with severe inflammatory bowel disease No life expectancy restrictions will apply Performance Status will not be considered

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localized prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Hoag Memorial Hospital Presbyterian

    Irvine, California, 92618, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.